{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-399377","form_type":"8-K","ticker":"RGNX","cik":"0001590877","company_name":"REGENXBIO Inc.","filed_at":"2026-09-23T20:05:14+00:00","discovered_at":"2026-09-23T20:06:00.271886+00:00","generated_at":"2026-09-23T20:07:11.818188+00:00","sec_items":["1.01"],"event_type":"litigation","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"REGENXBIO settles patent litigation with Sarepta for $39M payment","bullets":["Sarepta will pay $39.0 million to REGENXBIO within 10 days of settlement effective date (Sept 23, 2026).","Settlement resolves all patent infringement litigation over U.S. Patent Nos. 10,526,617 and 11,680,274 related to ELEVIDYS (SRP-9001).","Parties terminate litigation with prejudice; REGENXBIO and UPenn release current claims and covenant not to sue on AAVrh74-based products.","Covenant covers existing ELEVIDYS form and AAVrh74 capsid sequence, but does not extend to other gene therapy aspects."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-399377","json":"https://secwatch.observer/filing/0001193125-26-399377.json","markdown":"https://secwatch.observer/filing/0001193125-26-399377.md","text":"https://secwatch.observer/filing/0001193125-26-399377.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590877/000119312526399377/0001193125-26-399377-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590877/000119312526399377/rgnx-20260923.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-23T20:07:11.818188+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}